Joel R Hecht

Title(s)Professor of Clinical , Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.

    Collapse Research 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026 May 07; 394(18):1790-1802. Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou SHI, Lin T, Kar S, Tao L, Vora R, Hegde A, Aung K, Hong DS, RMC-6236-001 Investigators. PMID: 42090791.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    2. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 15; 406(10517):2360-2370. Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A, STELLAR-303 study investigators. PMID: 41130252.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    3. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. Eur J Cancer. 2025 Nov 17; 230:116034. Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Heinemann V, Cremolini C, Randolph Hecht J, Schmoll HJ, Nakayama G, Lenz HJ, Andre T, Shi Q, de Gramont A, Shitara K, Yoshino T. PMID: 41056789.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2025 06 20; 43(18):2094-2106. Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson AB, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, Grothey A, Yoshino T, André T, Shi Q, Chibaudel B. PMID: 40324123; PMCID: PMC12169864.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242. Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP. PMID: 39846804; PMCID: PMC11964177.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    6. A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. Target Oncol. 2025 May; 20(3):519-530. Eng C, Lakhani NJ, Philip PA, Schneider C, Johnson B, Kardosh A, Chao MP, Patnaik A, Shihadeh F, Lee Y, Song K, Jin D, Huo Y, Howland M, Fisher GA, Hecht JR. PMID: 40140179; PMCID: PMC12106125.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    7. Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. Oncologist. 2025 03 10; 30(3). Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J. PMID: 40156118; PMCID: PMC11953022.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    8. CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. BJC Rep. 2025 Feb 27; 3(1):10. Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, Falchook G, Cleary JM, Kim R, Krishnamurthy A, Marathe O, Youssoufian H, Ellis C, Waszak A, Ghosh S, Zhang H, Yablonski K, Shah SD, Diaz-Padilla I, Ulahannan S. PMID: 40016550; PMCID: PMC11868598.
      View in: PubMed   Mentions: 2  
    9. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 08; 22(6):366-375. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. PMID: 39151454.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    10. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncol. 2024; 20(24):1733-1743. Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. PMID: 39041200; PMCID: PMC11485978.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    11. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. Eur J Cancer. 2024 Aug; 207:114160. Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, Díaz-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A. PMID: 38896997.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    12. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 06; 22(2 D). Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. PMID: 38862008.
      View in: PubMed   Mentions: 176     Fields:    Translation:Humans
    13. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 04; 30(4):1013-1022. Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K. PMID: 38538867.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    14. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2023 10 20; 41(30):4714-4720. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. PMID: 37847995.
      View in: PubMed   Mentions: 17     Fields:    Translation:CTClinical Trials
    15. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023 04; 8(2):100884. Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. PMID: 36863095; PMCID: PMC10163149.
      View in: PubMed   Mentions: 22  Translation:HumansCellsCTClinical Trials
    16. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study. Acad Radiol. 2021 11; 28 Suppl 1:S210-S217. Haber Z, Lee EW, Price M, Wainberg Z, Hecht JR, Sayre J, Padia SA. PMID: 34099386.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORS. AACE Clin Case Rep. 2020 Sep-Oct; 6(5):e239-e242. Yang Y, Hecht JR, Liu ST, Cohen MJ, Hart SD, Wang HL, Heaney AP. PMID: 32984529; PMCID: PMC7511096.
      View in: PubMed   Mentions: 1  
    18. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. PMID: 32910338; PMCID: PMC8944136.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    19. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019 06; 11(8):705-723. Raman SS, Hecht JR, Chan E. PMID: 31045464.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    20. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018 06 01; 110(6):638-648. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR, Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD). PMID: 29267900; PMCID: PMC6005015.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    21. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. Oncologist. 2017 03; 22(3):243-e23. Hecht JR, Benson AB, Vyushkov D, Yang Y, Bendell J, Verma U. PMID: 28246207; PMCID: PMC5344646.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    22. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10; 34(5):443-51. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. PMID: 26628478.
      View in: PubMed   Mentions: 360     Fields:    Translation:HumansCTClinical Trials
    23. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4032-8. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. PMID: 26460303; PMCID: PMC4669589.
      View in: PubMed   Mentions: 351     Fields:    Translation:HumansCTClinical Trials
    24. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015 Sep; 41(8):653-9. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. PMID: 26220150.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    25. Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. Anticancer Res. 2015 Mar; 35(3):1567-73. Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S. PMID: 25750312.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    26. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun; 14(2):72-80. Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. PMID: 25982297.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    27. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015 Jan 01; 33(1):22-8. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. PMID: 25385741; PMCID: PMC4482837.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    28. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011 May 20; 29(15):1997-2003. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. PMID: 21464406.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    29. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010 Sep 20; 28(27):4240-6. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB. PMID: 20713879; PMCID: PMC3296668.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCellsCTClinical Trials
    30. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 Apr; 9(2):95-101. Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. PMID: 20378503.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    31. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010 Apr 01; 16(7):2205-13. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. PMID: 20332321.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    32. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10; 27(5):672-80. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. PMID: 19114685.
      View in: PubMed   Mentions: 311     Fields:    Translation:HumansCTClinical Trials
    33. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. Am J Health Syst Pharm. 2008 Jun 01; 65(11 Suppl 4):S15-21; quiz S22-4. Hecht JR. PMID: 18499885.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20; 25(15):1960-6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group. PMID: 17452677.
      View in: PubMed   Mentions: 1627     Fields:    Translation:HumansCTClinical Trials
    35. Successful gastrointestinal cancer drug development. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S24-7. Hecht JR. PMID: 17178281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. PMID: 15809480.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    37. Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer. Mol Imaging Biol. 2004 Jul-Aug; 6(4):208-13. Hecht JR. PMID: 15262236.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):13-5. Hecht JR, Blanke CD, Benson AB, Lenz HJ. PMID: 14569841.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003 Feb; 9(2):555-61. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. PMID: 12576418.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCellsCTClinical Trials
    40. Adjuvant therapy for gastric cancer: a reality at last. Curr Gastroenterol Rep. 2000 Dec; 2(6):478-81. Hecht JR. PMID: 11079050.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Joel's Networks
    Concepts (171)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (20)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California